This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apple's iWatch May Need FDA Approval -- and That's a Good Thing

NEW YORK (TheStreet) -- Not a day goes by where there isn't another iWatch rumor. Investors and customers alike are eagerly awaiting the iWatch. So why is Apple taking so long to release its iWatch?

We've heard the term "time is money." For Apple (AAPL - Get Report), time may be worth upwards of $50 billion in the first few years of iWatch sales.

Both Reuters and the Wall Street Journal believe Apple can sell between 50 and 60 million units. According to these reports, the iWatch, which is expected to come in various sizes, may be priced in a range from $300 to as high at $1,000.

Eva Dou and Lorraine Luk of the WSJ explain:

"Apple aims to address an overarching criticism of existing smartwatches that they don't provide functions significantly different from that of a smartphone."

Dou and Luk are referring to (among others) Samsung's (SSNLF) Gear line of smartwatches. Samsung has sold roughly 2 million of the devices last year. Of that total, 1.2 million were based on the Google's (GOOG) Android operating system. Other smartwatch makers include Sony (SNE) and Pebble.

The market is just beginning to bloom, however. According to the research firm IDC, the wearable industry will explode to 112 million devices in the next four years -- even though only 6 million units were sold in 2013. That's an annual growth rate of 450% over the next four years. 

But wearables have been a tough nut to crack.

Apple CEO Tim Cook once said that for Apple to disrupt the wearable market, the product has to be a "must-have" and not merely a "want." And this is why, according to Apple Toolbox, Apple has met with the Food and Drug Administration to asses the iWatch's "must-have" capabilities.

To separate the iWatch from the rest of the crowd, Apple is focusing not just on the device's electronic and technical capabilities. Apple wants the iWatch to emerge as an actual medical and health device.

To that end, Apple's announcement about its HealthKit at its Worldwide Developer Conference earlier this month hinted at the iWatch's potential health-monitoring sensors. It will will allow wearers to track oxygen saturation, calorie consumption, weight and sleep activity among other metrics.

Reports also suggest that the iWatch may offer a non-invasive way to check blood-sugar levels with the use of a glucometer. In other words, the device may be able to tell a wearer his or her glucose level without a needle or drawing blood. And that's where Apple's ambitions cross the jurisdiction of the FDA.

That's huge.

Under the Freedom of Information Act, Apple Toolbox requested and received a response from the FDA, which affirms that Apple officials met with the FDA last December to discuss mobile health.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SSNLF $1,050.00 5.00%
AAPL $95.18 1.60%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.12 -4.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs